Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Cardiology

Preventing Blood Clots in LVNC

At a Glance

In LVNC, the heart’s spongy appearance alone does not usually require a blood thinner. Anticoagulation is considered based on factors such as atrial fibrillation, reduced pumping function, a confirmed heart clot, or a previous stroke, while balancing bleeding risk.

One of the unique features of Left Ventricular Noncompaction (LVNC) is the presence of deep “pockets” or recesses within the heart muscle [1]. A common concern for patients is whether blood can become “trapped” or pool in these recesses, leading to the formation of blood clots (thromboembolism) [2]. If a clot forms in the heart and travels to the brain, it can cause a stroke [3].

However, modern research shows that simply having a “spongy” heart does not mean you are at high risk for clots [4]. For most patients, the risk of a stroke is more closely tied to how well the heart pumps and whether there are other rhythm issues [2][5].

When Are Blood Thinners Necessary?

Because blood thinners (anticoagulants) carry a real risk of serious bleeding, doctors do not prescribe them automatically. Having the “spongy” appearance of LVNC alone is not an indication to take a blood thinner [4][6].

Instead, anticoagulation is typically reserved for patients who meet specific criteria. Do not start or stop a blood thinner based on a general guide; this is highly individualized based on:

  • Reduced Pumping Function: When the heart is weak, blood moves more slowly, which can significantly increase the chance of a clot forming [7]. While some reviews suggest considering anticoagulation if the Ejection Fraction (EF) is below 40%, this is not a universal rule. If you are in a normal rhythm (sinus rhythm) with a low EF, prescribing a blood thinner is a case-by-case decision that must be weighed against bleeding risks [8][9].
  • Atrial Fibrillation (AFib): This irregular rhythm allows blood to pool in the upper chambers of the heart. If you have AFib, your doctor will use a stroke-risk assessment score to determine if anticoagulants are needed [10][11].
  • Documented Clot: If a scan shows a thrombus (blood clot) inside your heart, you will need a blood thinner to prevent the clot from growing or breaking off while your body naturally breaks it down over time [4][12].
  • Previous Stroke or Embolism: If you have already had a clot travel to another organ, you are at higher risk for a repeat event and will likely require a clinician-defined treatment plan [8].

Types of Blood Thinners

If you need an anticoagulant, your doctor will discuss which type is best for you:

  1. Direct Oral Anticoagulants (DOACs): These newer drugs (such as apixaban, rivaroxaban, or dabigatran) are well-established and often preferred for patients with nonvalvular Atrial Fibrillation because they do not require frequent blood tests [13][14]. They have been shown to be effective with a lower risk of certain serious bleedings compared to older drugs in many patients [15][16].
  2. Warfarin: This is an older medication that requires regular blood tests (to check your INR) to ensure the dose is correct [17]. While DOACs are convenient, Warfarin remains the preferred or better-established choice in some situations, particularly for treating a confirmed left-ventricular thrombus or if you have mechanical heart valves [18][19].

Monitoring and Safety

If you are being treated for a clot in your heart, the duration of therapy is individualized. It may last three to six months or longer, and you will have follow-up imaging (usually an echocardiogram, or sometimes a cardiac MRI) to evaluate the clot [20][21].

Crucial Safety Precautions:

  • Do not stop taking your blood thinner without medical advice.
  • Seek immediate emergency care if you experience: black or bloody stools, vomiting blood, severe headache, sudden one-sided weakness, a severe fall or head injury, or unusual large bruises.
  • Always consult your care team before taking NSAID pain relievers (like ibuprofen or naproxen), starting new supplements, or undergoing dental work or surgery.

Common questions in this guide

Does the spongy appearance of LVNC mean I need a blood thinner?
Not usually. The spongy appearance of LVNC alone is not an automatic reason to take an anticoagulant; clinicians also consider reduced pumping function, atrial fibrillation, a confirmed heart clot, a previous stroke or clot that traveled to another organ, and bleeding risk. The decision should be individualized with your care team.
When might someone with LVNC be prescribed anticoagulation?
Anticoagulation may be recommended when a heart clot is seen, when atrial fibrillation raises stroke risk, or after a previous stroke or embolic event. A low ejection fraction, particularly below 40%, may lead to a discussion, but it is not an automatic rule when the heart rhythm is normal. The expected benefit must be weighed against bleeding risk.
Are DOACs or warfarin used for clot prevention in LVNC?
Newer direct oral anticoagulants, or DOACs, are often used for people with nonvalvular atrial fibrillation and do not usually require frequent blood tests. Warfarin may be preferred or better established for some confirmed left-ventricular clots or for people with mechanical heart valves. Your clinician will consider the reason for treatment, kidney function, bleeding risk, and other factors.
How long might I take a blood thinner for a clot in the heart?
Treatment often lasts three to six months or longer, depending on the clot and your overall risk. Follow-up echocardiography or cardiac MRI is used to check whether the clot is resolving and to guide the treatment plan.
What warning signs require emergency help while I take a blood thinner?
Seek immediate emergency care for black or bloody stools, vomiting blood, a severe headache, sudden one-sided weakness, a severe fall or head injury, or unusually large bruises. These symptoms can signal serious bleeding or a stroke.
Can I take ibuprofen or supplements while using an anticoagulant?
Ask your care team before taking ibuprofen, naproxen, other nonsteroidal anti-inflammatory drugs, or new supplements because they may increase bleeding or interact with treatment. Contact the team before dental work or surgery as well.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Left ventricular noncompaction.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do I have any clinical risk factors for stroke, such as atrial fibrillation or a heart pumping function (EF) below 40%?
  2. 2.Based on my most recent imaging (Echo or MRI), was a blood clot (thrombus) actually seen in the 'spongy' areas of my heart?
  3. 3.If I need a blood thinner, am I a candidate for a newer Direct Oral Anticoagulant (DOAC) or is Warfarin preferred for my specific situation?
  4. 4.How does my kidney function and risk of bleeding affect the decision to start or stop anticoagulation?
  5. 5.If I have a blood clot, how often will we repeat my imaging to check on it?

References

References (21)
  1. 1

    Left Ventricular Non-Compaction: Evolving Concepts.

    Pittorru R, De Lazzari M, Migliore F, et al.

    Journal of clinical medicine 2024; (13(19)) doi:10.3390/jcm13195674.

    PMID: 39407735
  2. 2

    Prognostic Significance of Left Ventricular Noncompaction: Systematic Review and Meta-Analysis of Observational Studies.

    Aung N, Doimo S, Ricci F, et al.

    Circulation. Cardiovascular imaging 2020; (13(1)):e009712 doi:10.1161/CIRCIMAGING.119.009712.

    PMID: 31959004
  3. 3

    Long-Term Prognosis of Different Subtypes of Left Ventricular Noncompaction Cardiomyopathy Patients: A Retrospective Study in China.

    Gao S, Zhang S, Wang Z, et al.

    Journal of cardiovascular development and disease 2023; (10(9)) doi:10.3390/jcdd10090369.

    PMID: 37754798
  4. 4

    Anticoagulation Therapy in Specific Cardiomyopathies: Isolated Left Ventricular Noncompaction and Peripartum Cardiomyopathy.

    Kido K, Guglin M

    Journal of cardiovascular pharmacology and therapeutics 2019; (24(1)):31-36 doi:10.1177/1074248418783745.

    PMID: 29911432
  5. 5

    Bridging the gap between hypertrabeculation phenotype, noncompaction phenotype and left ventricular noncompaction cardiomyopathy.

    Vergani V, Lazzeroni D, Peretto G

    Journal of cardiovascular medicine (Hagerstown, Md.) 2020; (21(3)):192-199 doi:10.2459/JCM.0000000000000924.

    PMID: 31895132
  6. 6

    Left Ventricular Noncompaction Syndrome: Genetic Insights and Therapeutic Perspectives.

    Finsterer J, Stöllberger C

    Current cardiology reports 2020; (22(9)):84 doi:10.1007/s11886-020-01339-5.

    PMID: 32648009
  7. 7

    Predictors of life-threatening events in adult patients with left ventricular noncompaction.

    Blagova OV, Varionchik NV, Pavlenko EV, et al.

    World journal of cardiology 2025; (17(12)):112126 doi:10.4330/wjc.v17.i12.112126.

    PMID: 41479993
  8. 8

    Noncompaction cardiomyopathy: a substrate for a thromboembolic event.

    Tavares de Melo MD, de Araújo Filho JA, Parga Filho JR, et al.

    BMC cardiovascular disorders 2015; (15()):7 doi:10.1186/1471-2261-15-7.

    PMID: 25618133
  9. 9

    The Dilemma in the Management of Patients with Heart Failure with Reduced Ejection Fraction, Sinus Rhythm and Left Ventricular Spontaneous Echo Contrast: A Narrative Review.

    Alimi H, Tajik A

    Current cardiology reviews 2026; (22(1)):e1573403X363285 doi:10.2174/011573403X363285250519064030.

    PMID: 40444621
  10. 10

    The spongy heart paradox: balancing bleeding and clotting risk in left ventricular noncompaction cardiomyopathy.

    Nduka TC, Ndakotsu A, Udoh K, et al.

    Heart failure reviews 2026; (31(1)).

    PMID: 41779247
  11. 11

    A proposed strategy for anticoagulation therapy in noncompaction cardiomyopathy.

    Chimenti C, Lavalle C, Magnocavallo M, et al.

    ESC heart failure 2022; (9(1)):241-250 doi:10.1002/ehf2.13694.

    PMID: 34918480
  12. 12

    Management of left ventricular thrombus: a narrative review.

    Cruz Rodriguez JB, Okajima K, Greenberg BH

    Annals of translational medicine 2021; (9(6)):520 doi:10.21037/atm-20-7839.

    PMID: 33850917
  13. 13

    The Role of Antithrombotic Therapy in Heart Failure.

    Chrysohoou C, Magkas N, Antoniou CK, et al.

    Current pharmaceutical design 2020; (26(23)):2735-2761 doi:10.2174/1381612826666200531151823.

    PMID: 32473621
  14. 14

    Non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with heart failure and preserved, mildly reduced, and reduced ejection fraction: A systemic review and meta-analysis.

    Wulamiding K, Xu Z, Chen Y, et al.

    Frontiers in cardiovascular medicine 2022; (9()):949726 doi:10.3389/fcvm.2022.949726.

    PMID: 35966544
  15. 15

    Efficacy and safety of direct oral anticoagulants versus warfarin in patients with a left ventricular thrombus: an updated systematic review and meta-analysis of randomised controlled trials.

    Costa TA, Chagas GCL, Tavares de Sousa LM, et al.

    Open heart 2025; (12(2)) doi:10.1136/openhrt-2025-003542.

    PMID: 41265923
  16. 16

    Efficacy and Safety of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Left Ventricular Thrombus: A Systematic Review and Meta-Analysis.

    Khan M, Patel K, Edim GE, et al.

    Cureus 2025; (17(5)):e84941 doi:10.7759/cureus.84941.

    PMID: 40585598
  17. 17

    Reduced-Dose Apixaban in the Treatment of Left Ventricular Thrombus: A Report of 2 Cases.

    Bundrick AE, Bowers RD, Perkins SL, Baker CN

    Journal of pharmacy practice 2024; (37(2)):517-521 doi:10.1177/08971900221145051.

    PMID: 36475939
  18. 18

    When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review.

    Bejjani A, Khairani CD, Assi A, et al.

    Journal of the American College of Cardiology 2024; (83(3)):444-465 doi:10.1016/j.jacc.2023.10.038.

    PMID: 38233019
  19. 19

    Is transesophageal echocardiography necessary before electrical cardioversion in patients treated with non-vitamin K antagonist oral anticoagulants? Current evidence and practical approach.

    Gorczyca I, Uziębło-Życzkowska B, Krzesiński P, et al.

    Cardiology journal 2023; (30(4)):646-653 doi:10.5603/CJ.a2021.0129.

    PMID: 34671967
  20. 20

    Improving the management of left ventricular thrombus in a tertiary cardiology centre: a quality improvement project.

    Rahunathan N, Hurdus B, Straw S, et al.

    BMJ open quality 2023; (12(1)) doi:10.1136/bmjoq-2022-002111.

    PMID: 36631136
  21. 21

    The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction.

    Jones DA, Wright P, Alizadeh MA, et al.

    European heart journal. Cardiovascular pharmacotherapy 2021; (7(5)):398-404 doi:10.1093/ehjcvp/pvaa096.

    PMID: 32730627

This page is for informational purposes only and does not constitute medical advice about blood thinners or stroke risk in LVNC. Do not start, stop, or change an anticoagulant without guidance from your cardiology team.